Clinical Trials
13 trialsNCT06130826 2026-06-03
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Suspended
NCT03387553 2026-05-07
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT03384914 2026-03-06
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT07254858 2025-11-28
CISN-L
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT02276443 2025-08-01
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06908668 2025-04-03
Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06691594 2025-02-20
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT06084676 2024-07-17
Organoid Model Predictive of Response to Immunotherapies
Indiana University
Terminated
NCT04638751 2024-04-05
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Persephone Biosciences
Unknown
NCT04435964 2023-03-24
G-DEFINER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed
NCT05550090 2022-09-27
DreaminLMBC
Zhejiang Cancer Hospital
Unknown
NCT02539017 2016-08-10
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Withdrawn